2024
Risk factors for MACE and bleeding in atrial fibrillation patients undergoing surgery: Insights from the bridge trial
Shu L, Jack N, de Havenon A, Goldstein E, Khan F, Nguyen T, Henninger N, Siegler J, Stretz C, Perelstein E, Kala N, Rana M, Furie K, Douketis J, Yaghi S. Risk factors for MACE and bleeding in atrial fibrillation patients undergoing surgery: Insights from the bridge trial. Journal Of Stroke And Cerebrovascular Diseases 2024, 33: 107839. PMID: 38944363, DOI: 10.1016/j.jstrokecerebrovasdis.2024.107839.Peer-Reviewed Original ResearchMajor adverse cardiovascular eventsSymptomatic bleedingBridging therapyRisk factorsAtrial fibrillationLow-molecular-weight heparin bridging therapyTemporary interruption of warfarin therapyInterruption of warfarin therapyNonsteroidal anti-inflammatory drug useElective proceduresAnti-inflammatory drug useElective invasive proceduresHeparin bridging therapyRisk of adverse outcomesAdverse cardiovascular eventsPerioperative risk stratificationCox regression modelsIdentified risk factorsPost hoc analysisPatient undergoes surgeryLogistic stepwise regressionWarfarin therapyBridging anticoagulationAF patientsBleeding outcomes
2023
791-P: Comparing the Real-World Effects of Once-Weekly GLP-1 RAs and DPP-4 Inhibitors on Ischemic Stroke and Myocardial Infarction in Individuals with T2D and ASCVD
TAN X, LIANG Y, RAJPURA J, YEDIGAROVA L, NOONE J, XIE L, DE HAVENON A. 791-P: Comparing the Real-World Effects of Once-Weekly GLP-1 RAs and DPP-4 Inhibitors on Ischemic Stroke and Myocardial Infarction in Individuals with T2D and ASCVD. Diabetes 2023, 72 DOI: 10.2337/db23-791-p.Peer-Reviewed Original ResearchAtherosclerotic cardiovascular diseaseGLP-1 RAsMyocardial infarctionDPP-4iIschemic strokeCardiovascular eventsNovo NordiskGlucagon-like peptide-1 receptor agonistsWeekly glucagon-like peptide-1 receptor agonistMajor adverse cardiovascular eventsPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsRisk of MINew adult usersAdverse cardiovascular eventsRetrospective cohort studyPeptidase-4 inhibitorsDPP-4 inhibitorsType 2 diabetesReal-world evidenceDrug discontinuationBaseline characteristicsCohort studyOptum ClinformaticsReceptor agonistChange in Smoking Behavior and Outcome After Ischemic Stroke: Post-Hoc Analysis of the SPS3 Trial
Anadani M, Turan T, Yaghi S, Spiotta A, Gory B, Sharma R, Sheth K, de Havenon A. Change in Smoking Behavior and Outcome After Ischemic Stroke: Post-Hoc Analysis of the SPS3 Trial. Stroke 2023, 54: 921-927. PMID: 36876480, PMCID: PMC10050138, DOI: 10.1161/strokeaha.121.038202.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsAdverse cardiovascular eventsAcute ischemic strokeIschemic strokeCardiovascular eventsPersistent smokersPersistent smokingSPS3 trialSmoking statusMyocardial infarctionMajor adverse cardiovascular events outcomesCardiovascular event outcomesMajor cardiovascular outcomesSubsequent cardiovascular eventsHistory of hypertensionRisk of strokeEnd of studyPost Hoc AnalysisPrior smokersRandomization armCardiovascular outcomesFormer smokersMonth 3Primary outcomeTotal cohort